{"id":82108,"date":"2025-08-20T09:37:07","date_gmt":"2025-08-20T09:37:07","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/82108\/"},"modified":"2025-08-20T09:37:07","modified_gmt":"2025-08-20T09:37:07","slug":"unitedhealth-vs-novo-nordisk-which-healthcare-giant-fits-your-portfolio-novo-nordisk-nysenvo-unitedhealth-group-nyseunh","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/82108\/","title":{"rendered":"UnitedHealth Vs. Novo Nordisk: Which Healthcare Giant Fits Your Portfolio? &#8211; Novo Nordisk (NYSE:NVO), UnitedHealth Group (NYSE:UNH)"},"content":{"rendered":"<p class=\"block core-block\"><a href=\"https:\/\/www.benzinga.com\/money\/best-healthcare-stocks\" target=\"_blank\" rel=\"nofollow noopener\">Two healthcare giants<\/a>, UnitedHealth Group Inc UNH and Novo Nordisk A\/S NVO, are duking it out in very different ways for investors&#8217; attention. Both stocks have faced heavy losses this year\u2014UNH down 38.85% YTD, NVO down 38.59%. Yet, their underlying strategies couldn&#8217;t be more distinct.<\/p>\n<p>UnitedHealth: The Steady Hand<\/p>\n<p class=\"block core-block\">UnitedHealth trades at around $308, well below its 52-week high of $630.73, reflecting market concerns about profitability and broader pressures in the healthcare industry. Still, the stock is a dividend stalwart, offering a forward yield of 2.87% and a conservative payout ratio of 36.8%.<\/p>\n<p class=\"block core-block\">With a market capitalization of $279.4 billion and a modest P\/E ratio of 13.36, UnitedHealth offers income-focused investors a relatively safe haven amid market turbulence. Its gross profit margin is 17.9%, and quarterly net margins hover just above 3%, highlighting the company&#8217;s steady but slow-rolling profitability.<\/p>\n<p class=\"block core-block\">For those seeking to add stability to a portfolio battered by volatility, UnitedHealth&#8217;s cash flow reliability and consistent dividends are the key draws.<\/p>\n<p class=\"block core-block\">Read Also: <a href=\"https:\/\/www.benzinga.com\/trading-ideas\/long-ideas\/25\/08\/46825962\/unitedhealth-meta-moment-bleeding-out-or-just-a-bad-x-ray\" target=\"_blank\" rel=\"nofollow noopener\">UnitedHealth\u2019s Meta Moment? Bleeding Out Or Just A Bad X-Ray?<\/a><\/p>\n<p>Novo Nordisk: Growth On Steroids<\/p>\n<p class=\"block core-block\">On the flip side, Novo Nordisk is the growth engine that investors can&#8217;t ignore. Trading at around $54, down from its 52-week high of $139.74, NVO has seen bigger swings than UNH, but its fundamentals shine. <\/p>\n<p class=\"block core-block\">The Danish drugmaker boasts a jaw-dropping 83.3% gross margin and a 34.5% net margin, demonstrating why the market values its rapid revenue expansion so highly. Its forward dividend yield of 3.01% and a payout ratio of 44.3% also make it attractive for income seekers who can stomach higher risk. <\/p>\n<p class=\"block core-block\">With a P\/E of 13.8 and an enterprise value of $254.8 billion, investors are essentially getting high-margin growth at a reasonable valuation.<\/p>\n<p>Which Stock Fits Your Portfolio?<\/p>\n<p class=\"block core-block\">For U.S. investors, the choice comes down to strategy. If your priority is stability and a reliable income, UnitedHealth is the safer pick. However, if you&#8217;re seeking outsized growth and are willing to tolerate volatility, Novo Nordisk presents a compelling investment opportunity with generous margins and solid dividend support.<\/p>\n<p class=\"block core-block\">Either way, both names are defining how healthcare can serve different investment appetites in a challenging market.<\/p>\n<p class=\"block core-block\">Read Next: <\/p>\n<p class=\"block core-block\">Image: Shutterstock<\/p>\n","protected":false},"excerpt":{"rendered":"Two healthcare giants, UnitedHealth Group Inc UNH and Novo Nordisk A\/S NVO, are duking it out in very&hellip;\n","protected":false},"author":2,"featured_media":82109,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,8331,8335,8334,38213,38214,38215,8330,137,500,8329,62109,38218,62110,38221],"class_list":["post-82108","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-category-biotech","tag-category-general","tag-category-health-care","tag-category-long-ideas","tag-category-top-stories","tag-category-trading-ideas","tag-cms-wordpress","tag-health","tag-healthcare","tag-pageisbzpro-bz","tag-symbol-nvo","tag-symbol-unh","tag-tag-health-insurance","tag-tag-stories-that-matter"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/82108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=82108"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/82108\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/82109"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=82108"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=82108"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=82108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}